Results 221 to 230 of about 197,589 (314)

Management of HER2+ Breast Cancer with and without Brain Metastases in Saudi Arabia: Literature Insights and an Expert Survey of Current Practices. [PDF]

Breast Cancer (Dove Med Press)
Kullab S, Refae A, Altwairgi A, Abusanad A, Elsamany S, Abdelhafiez NA, Basulaiman B, Zahralliyali A, Alshangiti AA, Al-Mubarak M, Alwbari A, Alharbi A, Osman A, Kiwan H, Alaklabi S.   +14 more
europepmc   +1 more source

Trastuzumab deruxtecan (T-DXd) in HER2-expressing gynecological malignancies: Clinical evidence, safety profile, and future directions. [PDF]

Gynecol Oncol Rep
Arshad H, Arshad I, Rehman HM, Bibi S, Javaid MH, Roy RS.   +5 more
europepmc   +1 more source

Intelligent nano‐platforms in breast cancer therapy: Current advances and future perspectives

Precision Medical Sciences, EarlyView.
The smart nano platform in breast cancer treatment is designed with advanced nanocarriers, including liposomes, hydrogels, porous nanoparticles, and aptamer‐based systems. These systems are capable of targeted drug release and response to environmental stimuli.
Tina Rahimi, Moluk Aivazi
wiley   +1 more source

Long Non-Coding RNAs in HER2-Positive Breast Cancer: From Resistance Mechanisms to Translational Potential. [PDF]

Oncol Res
Vo TH, McNeela E, O'Donnovan O, Prakash Mehta J, Nguyen VH, Rani S.   +5 more
europepmc   +1 more source

RNA‐binding protein RBMS1: A new target for cancer diagnosis and treatment

Precision Medical Sciences, EarlyView.
This schematic illustrates the diverse regulatory roles of RNA‐binding motif single‐stranded interacting protein 1 (RBMS1) across multiple human cancers. In breast cancer, RBMS1 stabilizes B4GALT1 mRNA to promote PD‐L1 glycosylation, modulating tumor immune escape and immunotherapy efficacy.
Xingda Run, Shiwei Jiang, Kun Xu, Yu Fan, Yanwen Chen, Ziao Liu, Zengli Miao, Wei Tian   +7 more
wiley   +1 more source

HER2-Mutant Non-Small Cell Lung Cancer Podcast: Knowledge Is Power. [PDF]

Target Oncol
Subbiah V, Dietrich M, Le X.
europepmc   +1 more source

Molecular and genomic advances in breast cancer: A comprehensive review of predictive and therapeutic innovations

Precision Medical Sciences, EarlyView.
Breast cancer subtypes, estrogen receptor‐positive (ER+), HER2‐enriched, and TNBC, are defined by genomic and epigenetic signatures. Multi‐omics profiling, immunotherapy, liquid biopsy, and AI‐driven radiogenomics enable precision medicine. Tools like Oncotype DX and PAM50 support personalized care.
Samina Malik, Arif Malik, Shahzad Ahmad, Hassan Mohsin, Shazia Iqbal   +4 more
wiley   +1 more source

Decoding the landscape of bispecific antibodies in breast cancer: insights from a comprehensive trial analysis. [PDF]

Front Immunol
Yang S, Chuan Z, Yang S, Nie J.
europepmc   +1 more source

Endocrine therapy‐induced cancer‐related fatigue in hormone‐dependent malignancies: Mechanisms, impact, and management strategies

Precision Medical Sciences, EarlyView.
Multipathway schematic of endocrine therapy–induced cancer‐related fatigue. Endocrine interventions trigger four interacting mechanisms—neuroendocrine dysregulation, systemic inflammation, energy‐metabolic failure, and psycho‐behavioral amplification—that culminate in the multidimensional CRF phenotype.
Jiajing Jiang, Jun Lu, Sen Qin, Ruzhou Chen, Qiuchen Zhang, Lvqi He, Yubei Li, Jingyao Yan   +7 more
wiley   +1 more source

Temporal dynamics of prognostic factors in breast cancer survival. [PDF]

PLoS One
Tvete IF, Klemp M.
europepmc   +1 more source